Home › Occupations › Bioengineers and Biomedical Engineers › Indianapolis, IN
Bioengineers and Biomedical Engineers in Indianapolis, IN: H-1B salaries
33 labor condition applications for this occupation with a work site in Indianapolis, IN. Median offered base salary $106,434; middle half $89,850–$118,548.
By wage level
| Wage level | Median salary |
|---|---|
| Level I (entry) | $99,316 |
| Level II (qualified) | $91,700 |
| Level III (experienced) | $108,720 |
| Level IV (fully competent) | $141,540 |
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Employers
| Employer | LCAs | Median salary |
|---|---|---|
| Eli Lilly and Company | 14 | $109,360 |
| Roche Diagnostics Corporation | 5 | $106,434 |
| The RND Group LLC | 2 | $115,000 |
| Indiana University Indianapolis | 2 | $85,870 |
| Elanco US Inc. | 2 | $118,548 |
| PAXAFE, Inc. | 1 | $81,931 |
| Adjutant Solutions Group | 1 | $65,853 |
| NICO Corporation | 1 | $88,000 |
| Micronutrients USA, LLC | 1 | $95,000 |
| Novartis Services Inc. | 1 | $104,374 |
| Advanced Accelerator Applications USA, Inc. | 1 | $104,374 |
| IU Health Care Associates | 1 | — |
| Roche Diabetes Care, Inc. | 1 | $91,700 |
Job titles
- Verification Lead2
- Automation Scientist2
- Sr. Principal Engineer - IAPI2
- Sr. Associate - IDM QC2
- Assistant Professor2
- Lead Engineer2
- Advisor, Oligonucleotide Characterization1
- Chief Technology Officer1
- Principal Scientist1
- Technical Project Manager1
- Associate FES1
- Technical Project Manager and Systems Engineer1
- Product Development Engineer1
- Process Engineer1
- Sr. Engineer - Process - IAPI1
H-1B sponsors in Indianapolis, IN →
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).